ReviewCurrent treatment options in oncology2022
New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- FAPI: a solution to all, what about NENs?EJNMMI reports · 2026Review
- Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers.Journal of neuroendocrinology · 2026Review
- Multimodal strategies for diagnosing and treating thyroid cancer: Advances in basic and clinical research.Translational oncology · 2026Review
- Preliminary biological evaluation of a [EJNMMI radiopharmacy and chemistry · 2026Article
- Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.Insights into imaging · 2026Article
- Radiolabelled FAPI Radiotracers in Oncology: A Comprehensive Review of Current Diagnostic and Emerging Therapeutic Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Prognostic impact of discordant lesions on [Frontiers in nuclear medicine · 2026Article
- Feasibility of different lymph node metastases delineation approaches in [EJNMMI reports · 2025Article
- Development and Evaluation of a Vinyl Sulfone-Based Fluorine-18 Labeling Method for Constructing PSMA-targeted Prostate Cancer Imaging Agents.Molecular imaging and biology · 2025Article
- Dual PET Imaging with [Current oncology (Toronto, Ont.) · 2025Article
- The clinical benefits of [BMC medical imaging · 2025Article
- Review
- Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Evaluation of Inflammatory Activity of Extraocular Muscles in Thyroid Associated Orbitopathy by [Molecular imaging and biology · 2025Article
- Case Report: Adrenal gland splenosis mimicking a neuroendocrine tumor onFrontiers in medicine · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Comparison ofRadiology case reports · 2024Article
- Expression of the Calcium-Sensing Receptor on Normal and Abnormal Parathyroid and Thyroid Tissue.The Journal of surgical research · 2024Article
- A Framework for Interpretability in Machine Learning for Medical Imaging.IEEE access : practical innovations, open solutions · 2024Article
- The Advancing Role of Nanocomposites in Cancer Diagnosis and Treatment.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementNeuroendocrine neoplasms (NEN) are a heterogeneous group of tumours derived from cells of neuroendocrine origin and can potentially arise everywhere in the human body. The diagnostic assessment of NEN can be performed using a variety of PET radiopharmaceuticals. Well-differentiated NEN (NET) present a high expression of SSTR (somatostatin receptors) and can therefore be studied with 68Ga-DOTA-peptides ([68Ga]Ga-DOTANOC, [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE). Current guidelines recommend the use of SSTR imaging to assess disease extension at staging/restaging, follow-up, assessment of response to therapy and selection of patients who may benefit from radionuclide therapy (PRRT). [18F]F-FDG is used for the assessment of high-grade tumours (high-grade G2, G3 and NEC) and in every case, there is one or more mismatched lesions between diagnostic CT (positive) and SSTR-PET/CT (negative). [18F]F-DOPA is currently used for the assessment of medullary thyroid carcinoma, neuroblastoma, primary pheochromocytoma and abdominal paraganglioma. In recent years, however, several new tracers were designed exploiting the many potential targets of the neuroendocrine cell and were employed in clinical trials for both imaging and therapy. Currently, the real-life clinical impact of these tracers is still mostly not known; however, the favourable biodistribution (e.g. [68Ga]Ga-FAPI, SSTR antagonists) and the possibility to use new theranostic pairs may provide novel diagnostic as well as therapeutic options (e.g. [68Ga]Ga-PSMA, [64Cu]Cu-SARTATE, [68Ga]Ga-CXCR4) for NEN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.